

## Announcement of the Sales Partnership Agreement in Japan between Mochida and Shionogi regarding Insomnia Treatment Drug Daridorexant

---

This material is an English translation of the press release to be issued on November 1, 2023 in Japanese, and the Japanese release is given priority regarding content and interpretation.

November 1, 2023

Mochida Pharmaceutical Co., Ltd.  
Shionogi & Co., Ltd.

Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Naoyuki Mochida, hereinafter "Mochida") and Shionogi & Co., Ltd. (Head Office: Osaka City, Osaka; Chairman, President and CEO: Isao Teshirogi, hereinafter "Shionogi") wish to announce that they have entered into a sales partnership agreement (hereinafter "Sales Partnership Agreement") for the insomnia treatment drug, daridorexant (development code: ACT-541468, generic name: daridorexant hydrochloride) in Japan.

Daridorexant is an oral insomnia treatment drug that selectively inhibits bindings of the neuronal peptide (orexin) that promotes wakefulness to the receptors (OX1R and OX2R) and is expected to exert its effects by suppressing excessive wakefulness and transitioning into a sleep state. It is a dual orexin receptor antagonist (DORA). Daridorexant was approved in the US and Europe in January and April 2022, respectively, and is marketed by Idorsia Pharmaceuticals Ltd. (Head Office: Allschwil, Switzerland; CEO: Jean-Paul Clozel) in these and other approved territories as QUVIVIQ™.

In Japan, Mochida and Idorsia Pharmaceuticals Japan Co., Ltd. (Head Office: Minato-ku, Tokyo; President: Satoshi Tanaka, hereinafter "Idorsia Japan"), a subsidiary of SOSEI Group Corporation, have been jointly developing it. The application for manufacturing and marketing approval was made based on the results examining effectiveness and safety obtained in Phase III clinical trials targeting insomnia patients in Japan\*. After receiving manufacturing and marketing approval, Idorsia Japan and Mochida will jointly sell it in Japan. In addition, Mochida will work with Shionogi to sell the drug based on this Sales Partnership Agreement.

Mochida and Shionogi aim to expand treatment options for insomnia with this partnership and meet the needs of patients and medical professionals.

### Reference

\* Press release on October 31, 2023 by Mochida  
<https://www.mochida.co.jp/english/news/docs/2023/231031.pdf>

For Further Information, Contact:

Mochida: Public Relations, Corporate Planning Department (TEL. +81(0)3-3225-6303)  
SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>